← Peptide library
Peptide comparison
This page compares CJC-1295 and Ipamorelin side by side, drawing on the published reference data for each compound. Both are research peptides, and the points below summarize how each is characterized in its respective cited human studies. The aim is to lay out the reference details for both in one place, not to endorse either one.
CJC-1295
Ipamorelin
Investigational; not FDA-approved
Investigational/discontinued; not FDA-approved
Published Phase 1 human studies
Published Phase 2 human RCT; negative primary endpoint
Subcutaneous (CJC-1295 with DAC in cited study)
Intravenous in cited trial
Single or study-scheduled
Twice daily (IV study)
30–60 mcg/kg
0.03 mg/kg
CJC-1295 vs Ipamorelin: at a glance
| Attribute | CJC-1295 | Ipamorelin |
|---|---|---|
| Regulatory status | Investigational; not FDA-approved | Investigational/discontinued; not FDA-approved |
| Route | Subcutaneous (CJC-1295 with DAC in cited study) | Intravenous in cited trial |
| Dosing frequency | Single or study-scheduled | Twice daily (IV study) |
| Published range | 30-60 mcg/kg | 0.03 mg/kg |
| Evidence basis | Published Phase 1 human studies | Published Phase 2 human RCT; negative primary endpoint |
| What the source describes | Healthy-adult studies examined 30 and 60 mcg/kg among ascending doses; protocol-controlled | Postoperative ileus trial used 0.03 mg/kg IV twice daily up to 7 days; primary endpoint not met |
| Formulation | Weight-based conversion supported mathematically, but CJC-1295 with DAC must not be confused with 'no-DAC' products. | Do not use the IV study value as a subcutaneous protocol. No established outpatient injectable dose. |
Every value is quoted from each compound's own labeling or published trial, listed in the sources below. A published range describes what has been studied or labeled - it is not a recommendation, and this page does not advise choosing one compound over the other. There is no valid dose conversion between two different compounds.
What is not established
| Compound | Established dose range | Stated limitation |
|---|---|---|
| CJC-1295 | 30-60 mcg/kg | Limited data; FDA notes serious adverse events including increased heart rate and vasodilatory reaction. |
| Ipamorelin | 0.03 mg/kg | FDA notes immunogenicity/impurity concerns and serious adverse events including death in IV study context. |
Sources
| Compound | Primary source | Checked |
|---|---|---|
| CJC-1295 | PubMed - PMID 16352683 | 2026-06-24 |
| Ipamorelin | PubMed - PMID 25331030 | 2026-06-24 |
INTERACTIVE
Plan the CJC-1295 + ipamorelin co-draw
These two are commonly run together as a growth-hormone-secretagogue stack. Reconstitute each in its own vial, then plan the same-syringe co-draw — the tool works out the concentration and U-100 units to draw for each. Edit vial size, water, and dose to match your own. Arithmetic only — not medical advice.
CJC-1295 + ipamorelin co-draw calculator X
Reconstitute each vial, then plan the same-syringe co-draw and read U-100 units for each.
Arithmetic checks out. Confirm clinically, against the label, and against the actual vial before any use.
Independent check - dose mg / concentration mg/mL = volume. U-100 units = mL x 100.
Same-syringe co-draw. Reconstitute each peptide in its own vial, then draw them into one syringe.
- Reconstitute each peptide in its own vial — never add water to multiple peptides in one vial.
- Only co-draw peptides with the same diluent (e.g. both bacteriostatic water) and compatible pH.
- Draw and inject fresh — do not pre-mix and store; mixture stability is not established.
- No blended stack is clinically validated. Verify each component and confirm with a clinician.
Key differences
On regulatory status, both are investigational and neither is FDA-approved, though Ipamorelin is additionally noted as discontinued. Their evidence tiers differ: CJC-1295 is backed by published Phase 1 human studies, while Ipamorelin’s cited record is a published Phase 2 human randomized controlled trial whose primary endpoint was not met.
Reference comparison only. Not medical advice; verify with a clinician, product label, pharmacist, or approved research protocol.
Frequently asked questions
How are CJC-1295 and Ipamorelin administered in the cited studies?
They differ. The CJC-1295 figures here come from a subcutaneous study of CJC-1295 with DAC, while the Ipamorelin figures come from an intravenous clinical trial. Both are investigational and not FDA-approved.
What dose figures does this comparison reference?
Weight-based study figures shown above — CJC-1295 30–60 mcg/kg and Ipamorelin 0.03 mg/kg. These come from the cited research and are reference figures only, not dosing recommendations.
Can I calculate reconstitution for both here?
Yes — open either compound’s calculator from the buttons above to convert your own inputs into concentration (mg/mL), draw volume and U-100 syringe units.
Does this page recommend one over the other?
No. Both are investigational research peptides. This page is a neutral reference and does not assess efficacy, safety, or suitability — those decisions belong with a qualified professional.